Clinical

Treatment with relugolix and concomitant therapies for prostate cancer showed similar safety and efficacy to relugolix alone in a recent study.

The impaired reactivity may play a role in organ injury, the authors suggested, among patients who have immune-mediated thrombotic thrombocytopenic purpura (iTTP).

Dr Marshall shares insights directed at the use of real-world evidence [RWE] and its impact on unmet needs in colorectal cancer [CRC] treatment.

Natalie S. Callander, MD, director of the University of Wisconsin Carbone Cancer Center Myeloma Clinical Program, reviewed the treatment landscape at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference.

Patients with myelofibrosis (MF) with single-hit mutations had similar outcomes to patients with wild-type TP53.

The Protocol AC study analyzed visual acuity gains and cost if patients with diabetic macular edema started on bevacizumab, which costs less, and switched to aflibercept later, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.

Erin Michos, MD, MHS, opens a discussion surrounding the utilization of bempedoic acid for patients with intolerance to statin-based therapies.

Judicious use of caplacizumab (Cablivi) can reduce the risk of severe bleeding and help manage costs associated with the therapy in patients living with thrombotic thrombocytopenic purpura (TTP).

Dr Haumschild leads a discussion surrounding comorbidities associated with geographic atrophy.

David Lally, MD, highlights risk factors associated with geographic atrophy.

Female patients were most likely to experience onset of triple-negative myasthenia gravis (MG) between ages 0 to 9 years.

Assessing both physical and emotional functioning scales within cancer quality-of-life questionnaires at diagnosis may help predict survival in patients with lung cancer, a recent study found.

Idecabtagene vicleucel (ide-cel) led to significantly longer PFS and better therapy responses than standard regimens for patients with triple-class–exposed relapsed and refractory multiple myeloma.

In their closing thoughts, the expert panelists discuss the future of the disease state and treatment options, and how they expect provider, patient, and payer value perception to change in the future.

The panelists discuss how payers can best engage with the retinal disease community on a provider and patient level.

A review based on an expert panel discussion highlights a need for the inclusion of older patients in studies of immune checkpoint inhibitors for the first-line treatment of advanced non–small cell lung cancer (NSCLC).

Panelists provide their closing thoughts on the disease state and treatment landscape of multidrug-resistant HIV.

Dr Lopes and Mr Driffin discuss cost considerations and utilization barriers inhibiting treatment for patients with multidrug-resistant HIV.

Maria Lopes, MD, MS, and Mr Driffin explore total cost of care affected by various multidrug-resistant treatment regimens.

Two posters presented at the American Academy of Dermatology (AAD) annual meeting evaluated misconceptions and addressed concerns around the use of biosimilars in dermatology.

The tool can help clinicians stratify patients into high-risk and low-risk categories.

New data underscore the long-term implications of immune-mediated thrombotic thrombocytopenic purpura (iTTP) and atypical hemolytic-uremic syndrome (aHUS), both rare diseases.

A medical expert discusses real-world analyses surrounding the use of ctDNA.

Older age was also a risk factor for hospitalization and death in patients with myeloproliferative neoplasms (MPN) who contract COVID-19, the investigators found.

Although minimal residual disease (MRD) has emerged as a valuable prognostic marker across several hematological malignancies, its use in chronic lymphocytic leukemia (CLL) is mostly limited to clinical trials.